Serina Therapeutics (NYSEAMERICAN:SER) Posts Earnings Results

Serina Therapeutics (NYSEAMERICAN:SER) released its quarterly earnings results on Thursday. The company reported ($0.55) earnings per share for the quarter, FiscalAI reports.

Serina Therapeutics Stock Performance

Shares of SER stock traded down $0.04 during trading on Friday, reaching $2.81. 61,204 shares of the company’s stock traded hands, compared to its average volume of 1,871,698. The firm’s 50-day moving average is $2.08 and its 200 day moving average is $2.01. The company has a market capitalization of $42.10 million, a P/E ratio of -1.40 and a beta of 1.11. Serina Therapeutics has a 1 year low of $1.22 and a 1 year high of $7.92. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.24.

Analyst Ratings Changes

Separately, BTIG Research initiated coverage on shares of Serina Therapeutics in a report on Wednesday, July 1st. They issued a “buy” rating and a $8.00 price target on the stock. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $8.00.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.